Daré Bioscience (NASDAQ: DARE) posts September 2, 2025 corporate presentation

Rhea-AI Filing Summary

Daré Bioscience, Inc. furnished a new corporate presentation dated September 2, 2025, as Exhibit 99.1 to a current report. The company plans to use this presentation in meetings with securities market participants and others starting on that date.

A copy of the presentation is expected to be made available in the Investors section of Daré Bioscience’s website, on the “Presentations, Events & Webcasts” page under “Presentations.” The company notes that the presentation and the related disclosure are being furnished under Regulation FD and are not considered filed for liability purposes under the Exchange Act or automatically incorporated into other SEC filings.

false 0001401914 0001401914 2025-09-02 2025-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2025

DARE BIOSCIENCE, INC.

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36395		20-4139823
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock		DARE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Exhibit 99.1 to this report is a copy of a corporate presentation dated September 2, 2025, which is incorporated herein by reference. Daré Bioscience, Inc. (“Daré” or the “Company”) intends to use the presentation and its contents in various meetings with securities market participants and others, commencing on September 2, 2025.

The Company plans to make a copy of the presentation available in the “Investors” section of its website (https://ir.darebioscience.com), on the page titled “Presentations, Events & Webcasts,” under the heading “Presentations.” Information contained in, or that can be accessed through, the Company’s website is not incorporated by reference into this report.

The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Daré Bioscience corporate presentation, dated September 2, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DARÉ BIOSCIENCE, INC.
Dated: September 2, 2025	By:	/s/ Sabrina Martucci Johnson
	Name:	Sabrina Martucci Johnson
	Title:	President and Chief Executive Officer

-3-

FAQ

What did Daré Bioscience (DARE) disclose in this 8-K filing?

Daré Bioscience, Inc. reported that it has prepared a corporate presentation dated September 2, 2025, which is furnished as Exhibit 99.1. The company intends to use this presentation in meetings with securities market participants and others.

How will investors be able to access Daré Bioscience’s September 2, 2025 corporate presentation?

Daré Bioscience plans to make the presentation available in the Investors section of its website at https://ir.darebioscience.com, on the page titled “Presentations, Events & Webcasts,” under the heading “Presentations.”

Is the Daré Bioscience (DARE) corporate presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. As a result, it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless specifically referenced.

What SEC item does Daré Bioscience use for this disclosure?

The disclosure is made under Item 7.01 Regulation FD Disclosure, which is used for voluntarily providing information intended to ensure fair disclosure to all investors.

Who signed the Daré Bioscience 8-K related to the September 2, 2025 presentation?

The report was signed on behalf of Daré Bioscience, Inc. by Sabrina Martucci Johnson, who is the company’s President and Chief Executive Officer.

What exhibits are included with this Daré Bioscience (DARE) 8-K?

The 8-K lists Exhibit 99.1, the Daré Bioscience corporate presentation dated September 2, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.